Is Insmed Inc (INSM) overvalued? · rev $731.5M
Insmed Inc (INSM) is a biotechnology company listed on US.
This page asks whether Insmed Inc (INSM) looks expensive on cached numbers — not a short thesis.
Latest reported INSM revenue for 2026-06-30 was $731.5M. Net income was -$176.8M. INSM currently screens at market cap $20.42B.
INSM currently screens at market cap $20.42B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next INSM 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the INSM stock page for the full model, not this heading.
Not investment advice.